We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SOHONOS (Ipsen Pty Ltd)
Product name
SOHONOS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
palovarotene
Registration type
NCE/NBE
Indication
SOHONOS is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.